Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valrubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CHN2 | P52757 | 1/20 | 0.65 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 6/20 | 0.62 |
| ▸ | BLM | P54132 | 6/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valrubicin SCHEMBL12556870 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL12825 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL15372178 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL20541443 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL12824 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL4053249 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL1652790 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL22463650 | 0.99 | MEN1 (0.99) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL28183048 | 0.98 | MEN1 (0.97) | MEN1THRBKMT2AHTTLMNA | |
| SCHEMBL13394009 | 0.96 | MEN1 (0.93) | MEN1THRBKMT2AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075497-A | Use of NLRP3 agonist for tumor treatment | — | 2026-05-26 | — | — | CN | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | claimed |
| EP-3710001-B1 | COMPOUNDS AND METHODS FOR REGULATING, LIMITING, OR INHIBITING AVIL EXPRESSION | UNIV VIRGINIA PATENT FOUNDATION (US) | 2025-06-18 | — | — | EP | claimed |
| CN-120004785-A | Compounds and compositions for the treatment of diseases associated with STING activity | 诺华制药股份有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-119970803-A | Application of bacteria of genus Agrimonia in preparation of antitumor drugs | 深圳未知君生物科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| EP-4178588-B1 | ANTI-CANCER ACTIVITY OF PERBORATE SALTS | ALIYA PHARMACEUTICALS INC (CA) | 2025-05-07 | — | — | EP | claimed |
| EP-4547872-A1 | BIOMARKERS IN COLORECTAL CANCER | City of Hope (US) | 2025-05-07 | — | — | EP | claimed |
| EP-3986438-B1 | P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES | MERCK SHARP & DOHME LLC (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119735540-A | Compounds and compositions for the treatment of diseases associated with STING activity | 诺华制药股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| EP-3274044-B1 | ULTRASONIC URINARY BLADDER DRUG DELIVERY | VENSICA MEDICAL LTD (IL) | 2023-03-01 | — | — | EP | claimed |
| EP-3674302-B1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE HOLDINGS CORP (US) | 2023-03-01 | — | — | EP | claimed |
| EP-3851107-B1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2022-10-19 | — | — | EP | claimed |
| EP-3404118-B1 | METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS | Allarity Therapeutics Europe ApS (DK) | 2022-07-27 | — | — | EP | claimed |
| EP-3426657-B1 | 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES | Bayer Pharma AG (DE) | 2022-07-13 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3288558-B1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma AG (DE) | 2022-05-11 | — | — | EP | claimed |
| EP-3324954-B1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO LTD (TW) | 2022-03-09 | — | — | EP | claimed |
| EP-3354650-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3193917-B9 | VACCINE COMPOSITIONS COMPRISING TRYPTOPHAN 2,3-DIOXYGENASE OR FRAGMENTS THEREOF | IO BIOTECH APS (DK) | 2022-02-16 | — | — | EP | claimed |